-Dow Jones
SVB Leerink Maintains Outperform on Harpoon Therapeutics, Lowers Price Target to $25
SVB Leerink analyst Jonathan Chang maintains Harpoon Therapeutics (NASDAQ:HARP) with a Outperform and lowers the price target from $29 to $25.
Related Posts
Wells Fargo Upgrades Edwards Lifesciences to Overweight, Announces $126 Price Target
Wells Fargo analyst Larry Biegelsen upgrades Edwards Lifesciences (NYSE:EW) from Equal-Weight to Overweight and announces $126 price target.
EF Hutton Reiterates Buy on Innoviva, Maintains $22.5 Price Target
EF Hutton analyst Constantine Davides reiterates Innoviva (NASDAQ:INVA) with a Buy and maintains $22.5 price target.
Cooper Companies Reports Mixed Q4 Results
Cooper Companies Inc (NYSE:COO) reported that Q4 sales increased 11% Y/Y to $759.1 million, beating the consensus of $747.85 million.…